Yang Jinsong, Liu Cui, Liu Li, Yang Kunyu
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Mol Clin Oncol. 2025 Jun 4;23(2):69. doi: 10.3892/mco.2025.2864. eCollection 2025 Aug.
The rates of survival are low in patients with refractory advanced esophageal cancer in whom chemotherapy, radiotherapy and immunotherapy have failed. In the present report, the case of a 59-year-old male with dysphagia and paraneoplastic leukemoid reaction who was diagnosed with esophageal squamous cell cancer with multiple bone and left adrenal gland metastases, is described. Tumor progression continued after multiline chemotherapy with paclitaxel, platinum and irinotecan; immunotherapy with camrelizumab; and radiotherapy. Furthermore, the patient experienced grade 3 hematologic toxicities and immune-induced myocarditis. As fourth-line therapy, anlotinib was administered in combination with S-1. Thereafter, the patient's progression-free survival was 16.7 months, indicating that anlotinib combined with S-1 may be effective in refractory advanced esophageal cancer.
化疗、放疗和免疫治疗均失败的难治性晚期食管癌患者的生存率较低。在本报告中，描述了一例59岁男性患者，该患者有吞咽困难和副肿瘤性类白血病反应，被诊断为食管鳞状细胞癌伴多发骨转移和左肾上腺转移。在接受紫杉醇、铂类和伊立替康的多线化疗、卡瑞利珠单抗免疫治疗以及放疗后，肿瘤仍持续进展。此外，该患者还出现了3级血液学毒性和免疫性心肌炎。作为四线治疗，给予安罗替尼联合S-1治疗。此后，患者的无进展生存期为16.7个月，表明安罗替尼联合S-1可能对难治性晚期食管癌有效。
